BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4148-4154

  Gilmore, Paula M ^a   McCabe, Nuala ^a   Quinn, Jennifer E ^a   Kennedy, Richard D ^a   Gorski, Julia J ^a   Andrews, Heather N ^a   McWilliams, Stewart ^a   Carty, Michael ^a   Mullan, Paul B ^a   Duprex, W Paul ^a   Liu, Edison T ^b   Johnston, Patrick G ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MAMMAL CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MAP KINASE KINASE KINASE 3; MAP KINASE KINASE KINASES; PACLITAXEL; PLASMIDS; PROTEIN STRUCTURE, TERTIARY;

EID: 3042521552     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-4080     Document Type: Article

References (39)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science 1994;266:66-71.
2. Fitzgerald M, MacDonald D, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334: 143-9.
3. Berchuck A, Heron K-A, Carney ME, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:2433-7.
4. Wilson C, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Gen 1999;21:236-40.
5. Yang Q, Sakurai T, Mori I, et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001;92:54-60.
6. Zheng L, Pan H, Li S, et al. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 2000;4:757-68.
7. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
8. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404:201-4.
9. Scully R, Chen J, Plug A, et al. Association of BRCA1 with RAD51 in mitotic and meiotic cells. Cell 1997;88:265-75.
10. Zhong Q, Chen CF, Li S, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999;285:2747-50.
11. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
12. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998;58:5237-42.
13. Xu B, Kim S-T, Kastan MB. Involvement of Brca1 in S-phase and G2-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001;21:3445-50.
14. Xu B, O'Donnell AH, Kim S-H, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the ATM mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002;62:4588-91.
15. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-95.
16. Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-31.
17. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-86.
18. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000;275:33487-96.
19. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-8.
20. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of RAD51 and survival following treatment with the DNA cross-linking agent Cisplatin. J Biol Chem 2000;275:23899-903.
21. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy induced apoptosis. Cancer Res 2003;63:6221-8.
22. Andrews HN, Mullan PB, McWilliams S, et al. BRCA1 regulates the interferon γ-mediated apoptotic response. J Biol Chem 2002;277:26225-32.
23. Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 2001;276:17276-80.
24. Foray N, Marot D, Gabriel A, et al. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO 2003;22:2860-71.
25. Vidal M, Brachmann RK, Fattaey A, Harlow E, Boeke JD. Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions. Proc Natl Acad Sci USA 1996;93:10315-20.
26. Monteiro ANA, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996;93:13595-9.
27. Deacon K, Blank JL. MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases. J Biol Chem 1999;274:16604-10.
28. Wang TH, Wang HS, Ichijo H, et al. Microtubule-interfering agents activate c-Jun-N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998;273:4928-36.
29. 2-terminal kinase (JNK/SAPK). J Biol Chem 1998;43:28253-60.
30. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003;302:636-9.
31. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phosphor-protein binding domain. Science 2003;302:639-42.
32. Rodriguez M, Yu X, Chen J, Songyang Z. Phosphopeptide binding specificities of BRCT domains. J Biol Chem 2003;278:52914-8.
33. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Gen 2002;30: 285-9.
34. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 1998;281:1671-4.
35. Bonny C, Nicod P, Waeber G. IBI, a JIP-1-related nuclear protein present in insulin-secreting cells. J Biol Chem 1998;273:1843-6.
36. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 1998;281:1625-6.
37. Park SH, Zarrinpar A, Lim WA. Rewiring MAP kinase pathways using alternative scaffold assembly mechanisms. Science 2003;299:1025-7.
38. Wang TH, Popp DM, Wang HS, et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun-N-terminal kinase (JNK)-dependent and independent pathways in ovarian cancer cells. J Biol Chem 1999;274:8208-16.
39. Ham YM, Choi JS, Chun KH, Joo SH, Lee SK. The c-Jun N-terminal kinase 1 activity is differentially regulated by specific mechanisms during apoptosis. J Biol Chem 2003;278:50330-7.